Core Viewpoint - Huajian Medical (01931) is undergoing a strategic transformation to become a digital industry technology innovator, marking a shift from a traditional medical enterprise to a focus on blockchain and decentralized finance through the establishment of new companies and a name change [1][3][4]. Group 1: Strategic Transformation - Huajian Medical has announced a partnership with ETHK Group to jointly invest in two new companies, ETHK Inc and ETHK HOLDINGS LIMITED, aimed at developing a decentralized financial platform and a digital industry investment hub [4][6]. - The company will change its name from "IVD Medical Holding Limited" to "ETHK Labs Inc." and its Chinese name to "Huajian Digital Industry Group Limited," reflecting its ambition to become a core technology driver in the global digital industry [3][6]. Group 2: ETHK Ecosystem - The "ETHK" brand name combines "ETH" (Ether) and "K" (Kingdom), symbolizing a vision for a decentralized financial ecosystem that aligns with blockchain technology [7]. - ETHK Labs will focus on advanced technology research and development, serving as the technological foundation and innovation engine for the ETHK ecosystem [7]. Group 3: RWA Market Opportunity - The transformation aligns with the explosive growth of the Real World Asset (RWA) market, which saw a total locked value (TVL) increase from $8.6 billion to over $23 billion in the first half of 2025, a growth of over 260% [8][9]. - Predictions indicate that the global RWA market could reach $16.1 trillion by 2030, representing 10% of global GDP, positioning Huajian Medical to lead in RWA infrastructure development [9]. Group 4: Value Reconstruction - The strategic upgrade aims to enhance China's global digital financial influence by facilitating the "on-chain" transition of quality Chinese assets [10]. - The ETHK ecosystem is expected to address financing challenges for enterprises and promote global asset integration, contributing to financial inclusivity and stability [10]. - The company's valuation model is shifting from traditional earnings-based metrics to revenue-based metrics, reflecting its new focus on digital infrastructure [10].

Financial Data and Key Metrics Changes - The company's Q2 results were slightly below expectations, leading to initial stock pressure, but the stock price has since recovered to pre-release levels, indicating improved investor understanding of the company's guidance [3][4] - The company expects a significant increase in EPS in Q3 compared to Q2, driven by improvements in equipment sales and growth in the technology segment, which saw over 30% operating income growth year-over-year in Q2 [9][10] Business Line Data and Key Metrics Changes - The dental market in the U.S. has been relatively flat, with low single-digit growth, influenced by factors such as retirements and disruptions caused by the pandemic [11][12] - The company anticipates stronger Q4 revenues compared to Q3, particularly in equipment sales, due to tax incentive buying and a recovery in customer ordering patterns [6][8] Market Data and Key Metrics Changes - The company has observed a double-digit increase in renovation or expansion activities from customers, particularly among Dental Service Organizations (DSOs), indicating a stronger appetite for equipment investment compared to private practices [43][44] - The company is facilitating financing for approximately 50% of larger equipment sales, helping customers secure competitive rates [45] Company Strategy and Development Direction - The company is focusing on value creation projects aimed at optimizing gross profits and G&A costs, with expectations to provide updates on these initiatives in the upcoming Q3 earnings release [22][24] - The company is also exploring M&A opportunities, particularly in the medical and technology sectors, to enhance its offerings and expand its market presence [32][35] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about potential growth in the dental market with the expectation of declining interest rates, which could accelerate the opening of new dental practices [13][15] - The company is preparing for 2026 by assessing market growth rates and trends in core dental and medical segments, as well as the impact of tariffs on pricing and negotiations [20][21] Other Important Information - The company is in the assessment phase for its value creation projects, aiming for both short-term benefits and long-term sustainable value [25][29] - The CEO search is ongoing, with the board leading the effort to find a suitable successor [41][42] Q&A Session Summary Question: What investor feedback have you received post Q2? - Investors were initially concerned about the Q2 results but have since recovered confidence as they understand the company's guidance better [3][4] Question: How do you see the rest of the year playing out from a revenue perspective? - Q4 is expected to outperform Q3, particularly in equipment sales, driven by tax incentives and improved customer ordering patterns [6][8] Question: What are the potential headwinds and tailwinds for 2025? - The dental market has been flat, but potential interest rate declines could stimulate growth in new dental practices [11][13] Question: Can you elaborate on the value creation projects? - The company is currently assessing opportunities for optimizing gross profits and G&A costs, with updates expected in the Q3 earnings release [22][24] Question: What is the status of the CEO search? - The board is actively searching for a new CEO, acknowledging the challenge of finding a successor to Stanley Bergman [41][42]

Financial Data and Key Metrics Changes - The company's Q2 results were slightly below expectations, leading to initial stock pressure, but the stock price has since recovered to pre-release levels, indicating improved investor understanding of the company's guidance for the year [3][4] - EPS guidance suggests significant increases in Q3 and Q4 compared to Q2, driven by improvements in equipment sales and technology business performance, with over 30% operating income growth in the technology segment [9][10] Business Line Data and Key Metrics Changes - Equipment sales faced pressure in the first half of the year due to macroeconomic uncertainties, but there is confidence in equipment growth in the second half, supported by a healthy backlog and customer ordering patterns [6][8] - The technology segment showed strong momentum, with targeted investments leading to significant operating income growth [9] Market Data and Key Metrics Changes - The U.S. dental market has been relatively flat, with low single-digit growth, influenced by factors such as retirements and patient churn during the pandemic [11][12] - There is optimism for future growth in the dental market as interest rates potentially decline, which could accelerate the opening of new dental practices and increase demand for equipment [13][15] Company Strategy and Development Direction - The company is focusing on value creation projects aimed at optimizing gross profits and G&A costs, with expectations to provide updates on these initiatives in the upcoming Q3 earnings release [22][25] - M&A activity is primarily focused on the medical side, with successful integration of home solutions businesses and potential acquisitions in technology to enhance service offerings [35][38] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the need to understand market growth opportunities and the impact of tariffs on pricing and negotiations [21][22] - There is a belief that the dental market will see increased investment as economic conditions improve, particularly with declining interest rates [14][15] Other Important Information - The company is in the assessment phase for value creation projects, with expectations for both short-term and long-term benefits [26] - The new e-commerce platform has received positive feedback, enhancing customer experience and potentially increasing order sizes and margins [49][51] Q&A Session Summary Question: What are investors focused on post Q2? - Investors are focused on understanding initiatives to accelerate earnings and the company's guidance for the remainder of the year [3][4] Question: How do you see the rest of the year playing out from a revenue perspective? - Q4 is expected to be stronger than Q3 due to seasonal equipment buying and improved customer ordering patterns [6][8] Question: What are the potential headwinds and tailwinds for 2025? - The dental market has been flat, but potential interest rate declines could lead to growth in new practices and equipment demand [11][13] Question: Can you elaborate on the value creation projects? - The company is currently assessing opportunities for optimizing gross profits and G&A costs, with updates expected in the Q3 earnings release [22][25] Question: What is the status of the CEO search? - The board is leading the search for a new CEO, emphasizing the importance of finding an effective leader [43][44] Question: Are you seeing differences in capital demand between DSO and non-DSO customers? - DSOs show more appetite for equipment investment compared to private practices, influenced by their access to capital [45] Question: What feedback did you receive from the e-commerce platform launch in Europe? - Customers appreciated the smooth transition and improved functionality of the new platform, enhancing their overall experience [52][53]

Core Viewpoint - The company, Jingjiu Kangliao (00648.HK), has received a notification from the Stock Exchange regarding the temporary suspension of delisting procedures, contingent on further developments with the Securities and Futures Commission [1] Group 1: Company Operations - The company primarily engages in the distribution of medical and health equipment and products in Hong Kong, and its operations are continuing as normal in all significant aspects [1] - The board of directors will continue to monitor the impact of the suspension on the company's operations and financial performance, taking appropriate measures as necessary [1] Group 2: Stock Trading Status - The company's shares will remain suspended from trading until the conditions for resumption are met [1] - Shareholders and potential investors are advised to exercise caution when trading the company's shares [1]